Dublin, November 18, 2021 (GLOBE NEWSWIRE) – The “Global Auto Injector Market Outlook 2030” the report was added to ResearchAndMarkets.com offer.

The market is expected to generate sales of nearly $ 11,350 million by the end of 2030, compared to sales of around $ 3,120 million in 2020. The global auto-injector market is expected to grow with a CAGR of 13.9%. during the forecast period, i.e. 2021-2030.

An auto-injector is a medical drug delivery device designed to deliver a dose of a particular drug. Factors such as the growing need for auto-injectors in diabetic and allergic patients are expected to drive the market growth. Moreover, the increasing prevalence of allergic diseases and increasing cases of diabetes among individuals around the world are also expected to contribute to the growth of the market.

The global auto-injector market is segmented into numerous segments including segmentation by type, route of administration, drug type, application, demographics, distribution channel, end user, and region. The drug types segment is divided into epinephrine, insulin, Rebif and others, among which, epinephrine segment recorded the highest turnover of nearly $ 860 million in 2020, and further is expected to exceed one figure business of $ 3,230 million. by the end of 2030.

Based on the type, the market is segmented into Disposable Auto-Injectors and Reusable Auto-Injectors, among which, Disposable Auto-Injectors segment is expected to grow with the highest CAGR of around 14% during the forecast period.

The market in North America, by the end of 2030, is expected to reach sales of $ 4,400 million. The region market is segmented by country to United States and Canada among which, the United States market is expected to hold the highest market share during the forecast period. The country’s market is also expected to grow with the highest CAGR of nearly 14% during the forecast period.

Some of the top industry leaders featured in the report include

• Pfizer Inc.
• Comics
• Pharmaceutical company Adamis
• Biogen Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Antares Pharma inc.
• Sanofi SA
• Ypsomed AG
• SHL Medical SA

Main topics covered:

1. Market definition
1.1. Market definition
1.2. Market segmentation

2. Assumptions and acronyms

3. Research methodology
3.1. Research process
3.2. Primary research
3.3. Secondary research
3.4. Market size estimate

4. Executive Summary – Global Auto-Injector Market

5. Industry value chain analysis
5.1. Manufacturers
5.2. Distributors
5.3. End users

6. Market dynamics
6.1. Market factors
6.2. Market restriction
6.3. Market opportunity
6.4. Market trends

7. Regulatory and normative landscape

8. Industry risk analysis

9. Impact of COVID-19 on the global auto-injector market (2020-2029)
9.1. Impact on demand
9.2. Impact on auto-injector suppliers
9.3. Impact on strategy
9.4. Impact on manufacturers
9.5. Impact on end user spending
9.6. Impact on new market trends

10. Recent developments in the auto-injector market

11. Comparative analysis on the type of auto-injectors

12. Error analysis

13. Comparative analysis

14. Competitive landscape
14.1. Market share analysis, 2020
14.2. Company Profiles
14.2.1. Pfizer Inc.
14.2.2. Comics
14.2.3. Pharmaceutical company Adamis
14.2.4. Biogen Inc.
14.2.5. Teva Pharmaceutical Industries Ltd.
14.2.6. Mylan NV
14.2.7. Antares Pharma, Inc.
14.2.8. Sanofi SA
14.2.9. Ypsomed AG
14.2.10. SHL Medical SA

15. Global Auto-Injector Market 2020-2030
15.1. Market Snapshot
15.2. By value (million USD)

16. Global Auto-Injectors Market Segmentation Analysis 2020-2030
16.1. By type
16.1.1. Disposable Auto-Injector, 2020-2030F (USD Million)
16.1.2. Reusable Auto-Injector, 2020-2030F (USD million)
16.2. By route of administration
16.2.1. Subcutaneous, 2020-2030F (million USD)
16.2.2. Intramuscular, 2020-2030F (million USD)
16.3. By type of drug
16.3.1. Epinephrine, 2020-2030F (USD million)
16.3.2. Insulin, 2020-2030F (million USD)
16.3.3. Rebif, 2020-2030F (million USD)
16.3.4. Others, 2020-2030F (million USD)
16.4. By application
16.4.1. Rheumatoid Arthritis, 2020-2030F (USD million)
16.4.2. Anaphylaxis, 2020-2030F (million USD)
16.4.3. Diabetes, 2020-2030F (million USD)
16.4.4. Multiple Sclerosis, 2020-2030F (USD million)
16.4.5. Psoriasis, 2020-2030F (million USD)
16.4.6. Others, 2020-2030F (million USD)
16.5. By demography
16.5.1. Pediatrics, 2020-2030F (million USD)
16.5.1.1. Newborns, 2020-2030F (million USD)
16.5.1.2. Infants, 2020-2030F (million USD)
16.5.1.3. Children, 2020-2030F (millions USD)
16.5.1.4. Adolescents, 2020-2030F (million USD)
16.5.2. Adults, 2020-2030F (million USD)
16.5.3. Geriatrics, 2020-2030F (million USD)
16.6. By distribution channel
16.6.1. Hospital pharmacies, 2020-2030F (million USD)
16.6.2. Retail Pharmacies, 2020-2030F (USD million)
16.6.3. Online Pharmacies, 2020-2030F (million USD)
16.7. By end user
16.7.1. Hospitals and clinics, 2020-2030F (million USD)
16.7.2. Home Care Parameters, 2020-2030F (USD Million)
16.7.3. Outpatient Surgical Centers, 2020-2030F (USD million)
16.8. By region
16.8.1. North America
16.8.2. Europe
16.8.3. Latin America
16.8.4. Asia Pacific
16.8.5. Middle East and Africa

For more information on this report, visit https://www.researchandmarkets.com/r/7q3wmm